Affimed N.V

(NASDAQ:AFMD)

Latest On Affimed N.V (AFMD):

Date/Time Type Description Signal Details
2023-05-23 23:16 ESTNewsAffimed GAAP EPS of -€0.21, revenue of €4.51MN/A
2023-05-23 23:15 ESTNewsAffimed N.V. (AFMD) Q1 2023 Earnings Call TranscriptN/A
2023-05-23 08:37 ESTNewsAffimed GAAP EPS of -€0.21, revenue of €4.51BN/A
2023-05-23 08:37 ESTNewsAffimed gains FDA clearance to study lymphoma candidateN/A
2023-05-22 18:32 ESTNewsAffimed Q1 2023 Earnings PreviewN/A
2023-04-07 01:17 ESTNewsAffimed receives non-compliance letter from NasdaqN/A
2023-03-29 08:50 ESTNewsAffimed starts dosing of blood cancer drug in early-stage trialN/A
2023-03-24 06:33 ESTNewsAffimed N.V. (AFMD) Q4 2022 Earnings Call TranscriptN/A
2023-03-23 14:53 ESTNewsAffimed GAAP EPS of -€0.60, revenue of €41.35MN/A
2023-03-23 14:52 ESTNewsAffimed hits new 52-week low after Q4 2022 resultsN/A
2023-03-22 23:18 ESTNewsAffimed FY 2022 Earnings PreviewN/A
2023-03-09 12:50 ESTNewsAbCheck develops microfluidics tech for antibody discovery under Czech grant pactN/A
2023-02-21 07:31 ESTNewsAbCheck teams up to use microfluidics tech to discover antibodies for neurological disorderN/A
2023-02-18 02:31 ESTNewsAffimed Shifts Attention To Risky Combination Therapy With NK Cells For T-Cell LymphomaN/A
2022-12-22 10:08 ESTNewsAffimed receives approval to begin human trial for acute myeloid leukemia therapy in FranceN/A
2022-12-13 02:21 ESTNewsAffimed drops ~26% after plans to prioritize lead asset as a combination therapyN/A
2022-11-16 07:37 ESTNewsAffimed N.V. (AFMD) Q3 2022 Earnings Call TranscriptN/A
2022-11-15 14:55 ESTNewsAffimed GAAP EPS of -€0.11, revenue of €14.9MN/A
2022-11-10 12:38 ESTNewsAffimed ticks higher after updating Phase 1/2 data for tumor candidateN/A
2022-11-08 07:39 ESTNewsAffimed gains 22% after updating Phase 1/2 data for tumor candidateN/A
2022-11-03 22:52 ESTNewsAffimed soars 22% on team up with Artiva to develop combo cell therapyN/A
2022-10-26 12:37 ESTNewsAffimed: Data Readout Of AFM13 This Quarter Could Push Company ForwardN/A
2022-10-10 22:50 ESTNewsAffimed downgraded to hold at Stifel as pipeline lacks development clarityN/A
2022-08-11 22:36 ESTNewsAffimed GAAP EPS of -€0.13, revenue of €7.3MN/A
2022-08-11 22:36 ESTNewsAffimed to pull U.S. trial application for leukemia candidateN/A
2022-08-11 22:36 ESTNewsAffimed NV (AFMD) CEO Adi Hoess on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 05:48 ESTNewsAffimed Q2 2022 Earnings PreviewN/A
2022-06-29 11:25 ESTNewsAffimed: Preparing For Key Inflection PointsN/A
2022-06-02 03:03 ESTNewsAffimed N.V. (AFMD) CEO Adi Hoess on Q1 2022 Results - Earnings Call TranscriptN/A
2022-06-01 10:49 ESTNewsAffimed GAAP EPS of -€0.14, revenue of €8.02MN/A
2022-05-31 18:04 ESTNewsAffimed Q1 2022 Earnings PreviewN/A
2022-04-14 19:02 ESTNewsAffimed (AFMD) Investor Presentation - SlideshowN/A
2022-04-13 13:48 ESTNewsAffimed prices upsized stock offering of $90MN/A
2022-04-12 23:19 ESTNewsAffimed announces proposed common stock offeringN/A
2022-04-11 17:05 ESTNewsAffimed rises after data on blood cancer therapy from phase 1/2 studyN/A
2022-04-09 18:52 ESTNewsAffimed Stock: 3 Points For The BullsN/A
2022-04-01 02:21 ESTNewsAffimed GAAP EPS of -€0.48, revenue of €40.37MN/A
2022-04-01 02:21 ESTNewsAffimed N.V. (AFMD) CEO Adi Hoess on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-30 14:06 ESTNewsAffimed FY 2021 Earnings PreviewN/A
2021-12-08 20:40 ESTNewsAffimed, Roche commences patient recruitment in Phase 1/2a trial of AFM24 + atezolizumabN/A
2021-11-22 18:33 ESTNewsAffimed stock jumps 22% after reporting 100% ORR in Phase 1-2 lymphoma studyN/A
2021-11-11 00:44 ESTNewsAffimed reports Q3 resultsN/A
2021-11-11 00:43 ESTNewsAffimed drops nearly 10% after filing for mixed securities shelf offeringN/A
2021-11-11 00:43 ESTNewsAffimed N.V. (AFMD) CEO Adi Hoess on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-09 03:14 ESTNewsAffimed begins patient recruitment for phase 1/2a trial of cancer treatmentN/A
2021-10-12 01:11 ESTNewsAffimed: Preparing For A Bullish 2022N/A
2021-10-01 07:29 ESTNewsAffimed rallies as Stifel estimates a twofold rise in share priceN/A
2021-09-10 16:11 ESTNewsAffimed N.V. (AFMD) Investor Presentation - SlideshowN/A
2021-09-08 23:42 ESTNewsAffimed reports Q2 resultsN/A
2021-09-08 23:41 ESTNewsAffimed N.V. (AFMD) CEO Adi Hoess on Q2 2021 Results - Earnings Call TranscriptN/A

About Affimed N.V (AFMD):

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. and Roche. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD Quotes by TradingView

See Advanced Chart

General

  • Name Affimed N.V
  • Symbol AFMD
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 137
  • Fiscal Year EndDecember
  • IPO Date2014-09-12
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.affimed.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 18.26
  • Price/Book (Most Recent Quarter) 11.37
  • Enterprise Value Revenue 23.75
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.12
  • Profit Margin -175%
  • Return on Assets -23%
  • Return on Equity -114%
  • Earnings Per Share -$0.72
  • Revenue Per Share $0
  • Gross Profit 21.41 million
  • Quarterly Earnings Growth 401.4%
View More

Highlights

  • Market Capitalization 961.91 million
  • Analyst Target Price $11.46
  • Book Value Per Share $0.67
View More

Share Statistics

  • Shares Outstanding 114.79 million
  • Shares Float 82.4 million
  • % Held by Insiders 641%
  • % Held by Institutions 55.27%
  • Shares Short 7.47 million
  • Shares Short Prior Month 7.23 million
  • Short Ratio 4.35
  • Short % of Float 7%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 2.55
  • 52 Week High $8.58
  • 52 Week Low $1.5
  • 50 Day Moving Average 6.08
  • 200 Day Moving Average 5.07
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Affimed N.V (AFMD) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Affimed N.V (AFMD) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-10$10.55 million-$0.08-$0.1015.35%
2020-06-302020-08-11$2.93 million-$0.19-$0.16-15.51%
2020-03-312020-04-28$N/A-$0.21-$0.21-0.19%
2019-12-312019-12-31$3.93 million-$0.19-$0.190%
2019-09-302019-11-19$2.29 million-$0.19-$0.2213.39%
2019-06-302019-08-07$4.55 million-$0.19-$0.16-18.62%
2019-03-312019-05-22$12.73 million$0.03-$0.18118.84%
2018-12-312019-03-27$26.1 million$0.17-$0.18192.65%
2018-09-302018-11-07$354248.67-$0.22-$0.18-23.75%
2018-06-302018-08-08$174581.01-$0.15-$0.1712.06%
2018-03-312018-05-15$640915.24-$0.18-$0.194.05%
2017-12-312018-03-20$793000-$0.17-$0.198.88%
2017-09-302017-11-07$588000-$0.21-$0.20-4.56%
2017-06-302017-08-01$608000-$0.21-$0.236.02%
2017-03-312017-05-17$427000-$0.21-$0.21-0.67%
2016-12-312017-03-30$1.11 million-$0.18-$0.2834.27%
2016-09-302016-11-02$1.14 million-$0.34-$0.26-32.77%
2016-06-302016-08-10$2.21 million-$0.27-$0.24-11.67%
2016-03-312016-05-18$2.21 million-$0.28-$0.17-65.78%
2015-12-312016-03-30$1.62 million-$0.22-$0.221.73%
2015-09-302015-11-10$1.29 million-$0.24-$0.23-4.35%
2015-06-302015-08-04$2.57 million-$0.19-$0.16-18.75%
2015-03-312015-05-21$2.73 million-$0.06-$0.1764.71%
2014-12-312015-03-25$2.16 million-$0.22-$0.3026.67%
2014-09-302014-11-18$-934000$2.28-$0.241050%

Affimed N.V (AFMD) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Affimed N.V (AFMD) Chart:

Affimed N.V (AFMD) News:

Below you will find a list of latest news for Affimed N.V (AFMD) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Affimed N.V (AFMD) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-172.50.03CALL10 112339.24FALSE0.030
2025-04-1750.36CALL1 145993.53FALSE0.360
2025-04-177.50.03CALL10 28528.51FALSE0.030
2025-04-172.51.74PUT0 51673.42TRUE00
2025-04-1753.92PUT0 0891.07TRUE00
2025-04-177.50PUT0 0969.59TRUE00
2025-05-162.50.05CALL2 2241.98FALSE0.050
2025-05-1650CALL0 0638.72FALSE00
2025-05-167.50CALL0 0684.89FALSE00
2025-05-162.50PUT0 0673.41TRUE00
2025-05-1650PUT0 0480.63TRUE00
2025-05-167.50PUT0 0622.98TRUE00
2025-07-182.50.05CALL0 452158.5FALSE00
2025-07-1850.13CALL0 17419.44FALSE00
2025-07-187.50.05CALL0 1375.86FALSE00
2025-07-182.51.45PUT0 1601.93TRUE00
2025-07-1853.7PUT0 0917.57TRUE00
2025-07-187.50PUT0 0426TRUE00
2025-10-172.50CALL0 00FALSE00
2025-10-1750CALL0 0310.33FALSE00
2025-10-177.50CALL0 0332.9FALSE00
2025-10-172.50PUT0 0242.41TRUE00
2025-10-1750PUT0 0176.64TRUE00
2025-10-177.50PUT0 0354.65TRUE00

Latest AFMD Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST20$2.365
Jun 13, 2022 7:59 PM EST20$2.365
Jun 13, 2022 7:59 PM EST24$2.36
Jun 13, 2022 7:59 PM EST20$2.365
Jun 13, 2022 7:59 PM EST13$2.365

Affimed N.V (AFMD) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312520176020/0001193125-20-176020-index.htm
2018-11-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1608390/000000000018034557/0000000000-18-034557-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000083423720008210/0000834237-20-008210-index.htm
2017-02-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000090221917000024/0000902219-17-000024-index.htm
2018-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000090221918000050/0000902219-18-000050-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000090221919000079/0000902219-19-000079-index.htm
2020-01-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000090221920000033/0000902219-20-000033-index.htm
2020-05-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000090221920000381/0000902219-20-000381-index.htm
2019-12-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000093583619000658/0000935836-19-000658-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000093583620000105/0000935836-20-000105-index.htm
2016-09-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000094787116001513/0000947871-16-001513-index.htm
2017-01-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000094787117000069/0000947871-17-000069-index.htm
2017-03-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000094787117000193/0000947871-17-000193-index.htm
2016-07-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010316014559/0000950103-16-014559-index.htm
2016-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010316015480/0000950103-16-015480-index.htm
2016-11-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010316017598/0000950103-16-017598-index.htm
2016-12-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/0000950103-16-018537-index.htm
2016-12-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000095010316018713/0000950103-16-018713-index.htm
2017-01-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317000091/0000950103-17-000091-index.htm
2017-01-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317000176/0000950103-17-000176-index.htm
2017-01-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317000309/0000950103-17-000309-index.htm
2017-02-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317001198/0000950103-17-001198-index.htm
2017-02-096-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317001241/0000950103-17-001241-index.htm
2017-03-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317002898/0000950103-17-002898-index.htm
2017-03-3020-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1608390/000095010317002899/0000950103-17-002899-index.htm
2017-05-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317004683/0000950103-17-004683-index.htm
2017-05-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317004781/0000950103-17-004781-index.htm
2017-06-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317005949/0000950103-17-005949-index.htm
2017-08-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317007425/0000950103-17-007425-index.htm
2017-09-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317008864/0000950103-17-008864-index.htm
2017-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010317010895/0000950103-17-010895-index.htm
2018-01-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318000188/0000950103-18-000188-index.htm
2018-02-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318001302/0000950103-18-001302-index.htm
2018-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000095010318001711/0000950103-18-001711-index.htm
2018-02-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000095010318001885/0000950103-18-001885-index.htm
2018-02-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000095010318002059/0000950103-18-002059-index.htm
2018-02-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318002074/0000950103-18-002074-index.htm
2018-03-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318003152/0000950103-18-003152-index.htm
2018-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318003509/0000950103-18-003509-index.htm
2018-03-2020-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1608390/000095010318003510/0000950103-18-003510-index.htm
2018-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318006140/0000950103-18-006140-index.htm
2018-05-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318006296/0000950103-18-006296-index.htm
2018-06-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318007438/0000950103-18-007438-index.htm
2018-06-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318007610/0000950103-18-007610-index.htm
2018-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318009504/0000950103-18-009504-index.htm
2018-08-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318009978/0000950103-18-009978-index.htm
2018-10-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318011791/0000950103-18-011791-index.htm
2018-10-166-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318012094/0000950103-18-012094-index.htm
2018-10-22F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1608390/000095010318012289/0000950103-18-012289-index.htm
2018-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318012880/0000950103-18-012880-index.htm
2018-11-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1608390/000095010318013075/0000950103-18-013075-index.htm
2018-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010318013197/0000950103-18-013197-index.htm
2018-11-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000095010318013239/0000950103-18-013239-index.htm
2019-01-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010319000271/0000950103-19-000271-index.htm
2019-01-25SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000095010319000893/0000950103-19-000893-index.htm
2019-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010319004874/0000950103-19-004874-index.htm
2019-05-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010319006681/0000950103-19-006681-index.htm
2019-06-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010319007641/0000950103-19-007641-index.htm
2019-06-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000095010319008565/0000950103-19-008565-index.htm
2017-02-03SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000107261317000048/0001072613-17-000048-index.htm
2018-02-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000107261318000160/0001072613-18-000160-index.htm
2019-11-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000107261319000299/0001072613-19-000299-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000110465918009406/0001104659-18-009406-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000110465919008425/0001104659-19-008425-index.htm
2020-08-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000110465920092988/0001104659-20-092988-index.htm
2017-01-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000119312517013170/0001193125-17-013170-index.htm
2017-01-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000119312517016748/0001193125-17-016748-index.htm
2017-01-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312517017374/0001193125-17-017374-index.htm
2017-02-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312517030221/0001193125-17-030221-index.htm
2018-02-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312518051996/0001193125-18-051996-index.htm
2018-04-04SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312518107519/0001193125-18-107519-index.htm
2018-09-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312518277288/0001193125-18-277288-index.htm
2018-09-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312518283926/0001193125-18-283926-index.htm
2018-10-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312518291901/0001193125-18-291901-index.htm
2019-04-02SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312519095237/0001193125-19-095237-index.htm
2019-04-05SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312519099199/0001193125-19-099199-index.htm
2019-04-09SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312519101226/0001193125-19-101226-index.htm
2019-04-11SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1608390/000119312519103895/0001193125-19-103895-index.htm
2019-11-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000119312519287416/0001193125-19-287416-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312519287433/0001193125-19-287433-index.htm
2019-11-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000119312519289946/0001193125-19-289946-index.htm
2019-11-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312519291178/0001193125-19-291178-index.htm
2019-11-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312519295163/0001193125-19-295163-index.htm
2020-02-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312520022220/0001193125-20-022220-index.htm
2020-05-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1608390/000119312520141635/0001193125-20-141635-index.htm
2020-05-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312520141644/0001193125-20-141644-index.htm
2020-06-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312520176020/0001193125-20-176020-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312520190821/0001193125-20-190821-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312520199713/0001193125-20-199713-index.htm
2020-08-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000119312520209836/0001193125-20-209836-index.htm
2018-02-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000131924418000026/0001319244-18-000026-index.htm
2019-01-15SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000131924419000005/0001319244-19-000005-index.htm
2020-01-29SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000131924420000024/0001319244-20-000024-index.htm
2020-05-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000131924420000072/0001319244-20-000072-index.htm
2020-06-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000154600720000007/0001546007-20-000007-index.htm
2020-06-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000154600720000008/0001546007-20-000008-index.htm
2020-06-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000154600720000009/0001546007-20-000009-index.htm
2019-03-2720-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1608390/000155837019002456/0001558370-19-002456-index.htm
2019-08-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000155837019007372/0001558370-19-007372-index.htm
2020-04-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1608390/000155837020004420/0001558370-20-004420-index.htm
2020-04-2820-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1608390/000155837020004500/0001558370-20-004500-index.htm
2017-03-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000164525717000007/0001645257-17-000007-index.htm
2018-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1608390/000164525718000002/0001645257-18-000002-index.htm
2018-11-07EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1608390/999999999518002830/9999999995-18-002830-index.htm
2018-09-17CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1608390/999999999718007934/9999999997-18-007934-index.htm